Patent application number | Description | Published |
20090176859 | Cathepsin cysteine protease inhibitors - The present invention relates to a novel class of compounds mainly, leucinamide-amino-carboxylate derivatives of formula (I) wherein Y is CR | 07-09-2009 |
20090197883 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use - The instant invention provides compounds of Formula (I) which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents. | 08-06-2009 |
20100131236 | Apparatus and Method for Measuring Deflection of a Printed Circuit Board - Deflection measuring apparatus and methods are used to prevent overstress of printed circuit boards (PCB) prior and during testing. They can be used to verify in a HALT, HASS of ESS testing protocol, if the PCB testing fixture and vibration testing setup would be likely to cause failure of PCB components during pre- testing and testing procedures, which failure would otherwise not occur with faultless components. Furthermore, In the context of a PCB to be integrated to a system as a product such as a computer, the deflection measuring apparatus and methods are used to prevent overstress of PCBs at the system assembly stage, to ensure that operations involved, such as plugging of PCB connectors, will not cause PCB components failure, which would otherwise not occur with faultless components. | 05-27-2010 |
20100152185 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors. | 06-17-2010 |
20100179173 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY - Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome. | 07-15-2010 |
20100298347 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY - Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome. | 11-25-2010 |
20110230446 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS - This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. | 09-22-2011 |
20130035312 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS - This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. | 02-07-2013 |
20140051666 | PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHY- DRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE - In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1, 8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles. | 02-20-2014 |
20140256743 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS - This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. | 09-11-2014 |
20150057220 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS - Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer. | 02-26-2015 |